Telemental Health Research Highlights Telehealth Policy Barriers

Prior to the COVID-19 pandemic, telehealth research frequently focused on its use to access mental and behavioral health services, since the services were the most commonly considered as appropriate to receive virtually rather than in-person. As attention to and demand for telemental health access increased during the pandemic, additional studies have been released showing both trends and areas for future research as well as creating new policy. For instance, determining how many mental health clinicians have shifted their practices post-pandemic to primarily virtual, and how that trend interplays with federal and state policies requiring in-person visits. Additionally, with a shortage of mental health providers in many areas of the country, telehealth is a key tool to increase access to needed health care providers. However, a variety of other policy issues such as lack of payer reimbursement and digital equity continue to be challenges and limit telehealth’s ability to fully address access.


On January 31, 2024, the Department of Health and Human Services (HHS) finalized rules for the prescribing of buprenorphine through the use of telehealth (rules first proposed in December 2022). In these final rules, opioid treatment programs (OTPs) will be able to use telehealth to prescribe buprenorphine without an in-person visit. It is important to note that these final rules are not in regard to using telehealth to prescribe a controlled substance in general. This is a very specific rule that applies to OTPs and the use of telehealth to prescribe buprenorphine with some additional applications specifically to methadone. The broader policy of using telehealth to prescribe controlled substances without an in-person visit (or meeting one of the narrow exceptions found in federal statute) still remains a temporary allowance through the end of 2024.